Peptides Similar to MariTide

Peptides Related to MariTide#

MariTide is unique among anti-obesity therapies due to its antibody-peptide conjugate format, monthly dosing, and GIPR antagonism approach. It directly challenges the GIP agonism paradigm established by tirzepatide, demonstrating that opposite GIP modulation strategies can achieve similar weight loss outcomes.

Tirzepatide (Mounjaro/Zepbound)#

The most scientifically important comparison due to their opposite GIP strategies:

Both achieve approximately 20% weight loss, demonstrating that GIP pathway modulation in either direction enhances GLP-1-mediated weight loss. This pharmacological paradox is a major research question in the field.

Semaglutide (Wegovy)#

MariTide offers potential advantages over GLP-1 monoagonism:

• Dual mechanism (GLP-1 agonism + GIPR antagonism) vs GLP-1 only
• Monthly vs weekly dosing
• ~20% vs ~15-17% weight loss
• Semaglutide has extensive long-term and CV outcomes data

Retatrutide (Eli Lilly)#

Different multi-receptor approaches:

• Retatrutide: GIP + GLP-1 + glucagon triple agonism (~24.2% weight loss)
• MariTide: GLP-1 agonism + GIPR antagonism (~20% weight loss)
• Retatrutide achieves higher weight loss but with weekly peptide dosing
• Both in Phase 3

Summary Comparison#

Comparison Context#

MariTide belongs to the Metabolic category of research peptides. Comparing MariTide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.

Detailed Comparisons#

The following peptides and compounds are most closely related to MariTide in mechanism, indication, or therapeutic category:

MariTide vs Tirzepatide#

Similarity: Very High - Both target GLP-1R and GIPR, but with opposite GIP strategies (MariTide antagonizes GIPR; tirzepatide activates GIPR)

Key Differences: Fundamentally different GIP approach. MariTide is an antibody-peptide conjugate (153.5 kDa) with monthly dosing; tirzepatide is a peptide (4.8 kDa) with weekly dosing. Both achieve ~20% weight loss.

Advantages of Tirzepatide: Monthly dosing (vs weekly), 21-day half-life, potential for different metabolic effects via GIPR antagonism

Disadvantages of Tirzepatide: Not approved (tirzepatide is approved), larger molecule (immunogenicity risk), earlier development stage, no head-to-head data

Researchers choosing between MariTide and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.

MariTide vs Semaglutide#

Similarity: High - Both activate GLP-1 receptors; MariTide adds GIPR antagonism and has much longer half-life

Key Differences: Semaglutide is a selective GLP-1 agonist peptide; MariTide adds GIPR antagonism via antibody component. Semaglutide is weekly/daily; MariTide is monthly. Different molecular formats.

Advantages of Semaglutide: Monthly dosing, dual mechanism (GLP-1 agonism + GIPR antagonism), ~20% vs ~15-17% weight loss

Disadvantages of Semaglutide: Not approved, larger molecule, no CV outcomes data, no oral formulation, potential immunogenicity

Researchers choosing between MariTide and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.

MariTide vs Retatrutide#

Similarity: Moderate - Both are next-generation multi-receptor obesity therapies with different receptor targets and approaches

Key Differences: Retatrutide is a triple peptide agonist (GIP + GLP-1 + glucagon); MariTide is an antibody-peptide conjugate (GLP-1 agonist + GIPR antagonist). Completely different molecular formats and mechanisms.

Advantages of Retatrutide: Monthly dosing, unique GIPR antagonism approach

Disadvantages of Retatrutide: Lower peak weight loss (~20% vs ~24.2%), no glucagon receptor activity, larger molecule with immunogenicity considerations

Researchers choosing between MariTide and Retatrutide should consider the development stage, available evidence, and specific research objectives when making their selection.

MariTide vs CagriSema#

Similarity: Moderate - Both are multi-mechanism anti-obesity therapies achieving ~20% weight loss, but with different targets and approaches

Key Differences: CagriSema targets amylin + GLP-1 as two peptides; MariTide targets GLP-1 agonism + GIPR antagonism as an antibody-peptide conjugate. Completely different receptor combinations and molecular formats.

Advantages of CagriSema: Monthly dosing (vs weekly SC), single injection, unique GIPR antagonism

Disadvantages of CagriSema: Less advanced than CagriSema (NDA filed), different mechanism, potential immunogenicity from antibody component

Researchers choosing between MariTide and CagriSema should consider the development stage, available evidence, and specific research objectives when making their selection.

MariTide vs Survodutide#

Similarity: Moderate - Both are dual-mechanism anti-obesity therapies targeting different receptor combinations

Key Differences: Survodutide is a dual GLP-1/glucagon agonist peptide; MariTide is a GLP-1 agonist / GIPR antagonist antibody-peptide conjugate. Different second mechanism and different molecular format.

Advantages of Survodutide: Monthly dosing, unique GIPR antagonism approach, ~20% vs ~18.7% weight loss

Disadvantages of Survodutide: Earlier development, antibody format (immunogenicity), no MASH-specific data

Researchers choosing between MariTide and Survodutide should consider the development stage, available evidence, and specific research objectives when making their selection.

Related Reading#

• MariTide overview and research guide
• MariTide research evidence
• MariTide dosing protocols